Emmaus Competitors

Delisted . USA . 
Stock . Emmaus Life Sciences
EMMADelisted Stock  USD 0.26  0.00  0.00%   
Emmaus Life Sciences competes with Cell Source, Anebulo Pharmaceuticals, Adagene, Acrivon Therapeutics,, and AnaptysBio; as well as few others. The company conducts business under Pharmaceuticals sector and is part of Health Care industry. Analyzing Emmaus Life competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Emmaus Life to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in population.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Emmaus Life competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.260.260.26
Details
Intrinsic
Valuation
LowRealHigh
0.230.230.29
Details

Emmaus Life Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Emmaus Life and its competitors represents the degree of relationship between the price movements of corresponding otcs. A correlation of about +1.0 implies that the price of Emmaus and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Emmaus Life Sciences does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
ANEB
+ 0.86
PTE
ZIVO
+ 0.84
PTE
ANEB
+ 0.78
ZIVO
ANEB
+ 0.55
KLDO
PTE
+ 0.44
KLDO
AMTI
+ 0.36
NRXPW
  
High negative correlations   
CLCS
- 0.67
KLDO
PTE
- 0.55
CLCS
ANEB
- 0.49
CLCS
ZIVO
- 0.44
AMTI
ANEB
- 0.43
AMTI
ZIVO
- 0.37
CLCS

Risk-Adjusted Indicators

There is a big difference between Emmaus OTC Stock performing well and Emmaus Life OTC Stock doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Emmaus Life's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
NRXPW  9.73  1.17  0.06 (0.73) 12.98 
(10.55)
 24.50 
(28.29)
 58.29 
KLDO  190.11  98.83  0.00 (11.99) 0.00 
 0.00 
 50.00 
(25.00)
 4,849 
AMTI  5.08  0.21  0.02 (0.14) 5.70 
(6.89)
 11.11 
(10.34)
 36.60 
SCPS  13.35  0.67  0.03 (0.16) 17.61 
(16.96)
 35.42 
(24.69)
 94.02 
CLCS  10.41  2.07  0.13 (0.88) 10.74 
(16.92)
 45.24 
(24.56)
 92.05 
ATRX  7.63  0.31  0.01 (0.11) 11.29 
(14.94)
 20.00 
(31.58)
 67.29 
PTE  9.13 (1.92) 0.00  2.88  0.00 
 0.00 
 16.82 
(29.29)
 82.60 
ZIVO  3.01 (0.65) 0.00 (4.99) 0.00 
 0.00 
 5.31 
(6.67)
 36.36 
ANEB  4.33  0.10  0.01 (1.63) 5.78 
(5.03)
 7.64 
(9.76)
 29.60 
All Fundamental Data

Emmaus Life Competitive Analysis

The better you understand Emmaus Life competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Emmaus Life's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Emmaus Life's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
EMMA NRXPW KLDO AMTI SCPS CLCS ATRX PTE ZIVO ANEB
 0.00 
 0.26 
Emmaus
 30.00 
 0.07 
NRx
 0.00 
 0.01 
Kaleido
 0.00 
 0.33 
Applied
 0.00 
 0.10 
Scopus
 2.04 
 0.48 
Cell
 0.00 
 0.72 
Adhera
 10.29 
 0.07 
Polarityte
 0.55 
 1.81 
Zivo
 4.94 
 1.70 
Anebulo
Market Volatility
(90 Days Market Risk)
Very steady
Out of control
Very steady
Very steady
Very steady
Out of control
Very steady
Very steady
Very steady
Dangerous
Market Performance
(90 Days Performance)
Very Weak
Good
Very Weak
Very Weak
Very Weak
OK
Very Weak
Very Weak
Very Weak
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Dangerous
High
Dangerous
Dangerous
Dangerous
Low
Dangerous
Dangerous
Dangerous
Low
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Strong Buy
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Strong Sell
Not Rated
Not Rated
Not Rated
Strong Sell
Not Rated
Not Rated
Not Rated
Strong Sell
Current Ratio
0.14
4.58
1.42
6.25
0.31
0.03
0.05
6.52
2.08
30.4
Net Asset
56.73 M
7.32 M
50.14 M
107.45 M
8.19 M
313.77 K
196 K
22.85 M
2.12 M
4.07 M
Profit Margin
-1.14
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
EBITDA
(12.76 M)
(30.02 M)
(85.09 M)
(127.22 M)
(26.18 M)
(4.11 M)
(4.92 M)
(24.29 M)
(8.73 M)
(8.05 M)
Operating Margin
-0.65
N/A
-79.28
N/A
N/A
N/A
N/A
-298.68
-133.25
N/A
Current Valuation
49.41 M
N/A
(16.73 M)
(5.88 M)
1.18 M
59.65 M
10.55 M
(1.7 M)
2.02 M
68.44 M
Price To Book
N/A
N/A
0.0044
0.7
2.42
N/A
N/A
0.29
17.86
36.78
Retained Earnings
(82.78 M)
(253.15 M)
(197.63 M)
(365.97 M)
N/A
(21.7 M)
(42.43 M)
(516.23 M)
(115.8 M)
(65.4 M)
Current Asset
9.19 M
N/A
72.93 M
N/A
N/A
213.56 K
20.36 M
N/A
28.93 K
N/A
Beta
1.97
1.27
0.42
2.29
1.16
-64.41
-0.14
1.15
0.27
-1.01
Number Of Employees
58
N/A
76
13
9
1
12
42
8
2
Shares Outstanding
49.56 M
N/A
42.62 M
41.85 M
21.09 M
35.25 M
3.16 M
7.38 M
1.82 M
25.93 M
Cash Flow From Operations
(1.25 M)
(21.66 M)
(77.09 M)
(93.9 M)
(11.42 M)
(3.38 M)
(665 K)
(22.6 M)
(7.1 M)
(8.09 M)
Annual Yield
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
0.0424
N/A
Total Debt
4.65 M
9.16 M
5.55 M
36.12 M
2.54 M
6.5 M
7.35 M
3.36 M
445.18 K
260.58 K
Return On Equity
N/A
-6.83
-5.81
-1.58
-15.6
N/A
N/A
-0.55
-39.56
-1.14
Z Score
1.6
N/A
-6.3
-7.95
-9.9
N/A
N/A
-34.2
-87.31
N/A
Return On Asset
-0.12
-1.16
-1.0
-0.51
-4.61
-3.78
-4.48
-0.57
-1.65
-0.66
Number Of Shares Shorted
41.22 K
1.21 K
2.34 M
292.87 K
23.77 K
N/A
2.05 K
120.43 K
35.47 K
2.67 K
Book Value Per Share
-0.76
-1.42
0.25
0.4
-0.26
-0.34
-6.9
1.74
-0.63
0.15
Current Liabilities
7.25 M
N/A
10.39 M
N/A
N/A
8 M
3.88 M
N/A
4.97 M
N/A
Total Asset
56.73 M
7.32 M
50.14 M
107.45 M
8.19 M
313.77 K
196 K
22.85 M
2.12 M
4.07 M
Debt To Equity
-0.041
0.016
2.05
0.38
0.61
-1.04
56.3
0.09
0.28
N/A
Short Ratio
0.48
N/A
29.34
0.96
0.22
N/A
3.24
3.19
6.65
1.94
Target Price
4.0
N/A
22.0
1.0
12.0
N/A
N/A
0.8
36.0
6.0
Shares Owned By Institutions
N/A
N/A
0.36
37.2
2.15
N/A
N/A
9.38
4.44
28.18
Market Capitalization
24.28 M
714.61 M
421.96 K
11.01 M
2.17 M
10.61 M
2.18 M
1.78 M
2 M
42.79 M
Price To Earning
-1.6
N/A
-1.45
N/A
N/A
-3.28
-125.83
N/A
-1.95
N/A
Price To Earnings To Growth
N/A
N/A
N/A
-0.01
N/A
N/A
N/A
-0.07
N/A
N/A
Price To Sales
1.06
N/A
0.0425
N/A
N/A
N/A
8.23
2.78
2639.17
N/A
Net Income
(15.95 M)
(30.15 M)
(90.29 M)
(126.33 M)
(26.95 M)
(5.47 M)
(6.35 M)
(7.83 M)
(8.75 M)
(8.2 M)
Earnings Per Share
-0.18
-6.25
-2.16
-1.89
-1.51
-0.19
-0.52
-0.58
-5.33
-0.32
Shares Owned By Insiders
38.73
N/A
0.73
21.35
50.66
32.13
21.87
3.42
25.23
64.22
Revenue
20.61 M
N/A
1.1 M
N/A
N/A
N/A
N/A
814 K
N/A
N/A
Working Capital
1.95 M
(12.16 M)
62.54 M
48.93 M
N/A
(7.79 M)
16.49 M
11.19 M
(126.04 K)
3.25 M
Cash And Equivalents
982 K
24.55 M
38.47 M
95.83 M
1.16 M
93.09 K
849 K
20.88 M
5.08 M
14.55 M
Cash Per Share
0.02
0.36
0.9
2.46
0.05
N/A
0.01
3.78
0.54
0.62
Gross Profit
17.3 M
N/A
(66.7 M)
(42.08 M)
N/A
N/A
(157 K)
198 K
20 K
N/A
Day Typical Price
0.26
0.0791
0.01
0.32
0.1
0.48
0.72
0.0742
1.82
1.72
Accumulation Distribution
N/A
0.28
N/A
0.0606
0.0909
0.0208
N/A
0.18
0.0688
0.12
Market Facilitation Index
N/A
0.0274
N/A
0.02
0.01
0.01
N/A
0.0144
0.13
0.23
Daily Balance Of Power
0.0
(1.09)
0.0
N/A
N/A
(1.00)
0.0
0.4861
(0.08)
0.3478
Period Momentum Indicator
N/A
(0.03)
N/A
N/A
N/A
(0.01)
N/A
0.007
(0.01)
0.08
Rate Of Daily Change
1.0
0.7
1.0
1.0
1.0
0.98
1.0
1.1
0.99
1.05
Day Median Price
0.26
0.0837
0.01
0.32
0.11
0.48
0.72
0.0738
1.83
1.74
Price Action Indicator
N/A
(0.03)
N/A
0.01
(0.01)
N/A
N/A
0.0047
(0.02)
0.005
Coefficient Of Variation
12169.09
1215.63
695.41
3673.58
3349.94
826.3
4964.62
(763.07)
(722.69)
6568.0
Mean Deviation
6.43
9.73
190.11
5.08
13.35
10.41
7.63
9.13
3.01
4.33
Jensen Alpha
0.0887
1.17
98.83
0.2098
0.6736
2.07
0.3091
(1.92)
(0.65)
0.0991
Total Risk Alpha
(0.20)
0.7484
79.54
(0.01)
0.0305
1.55
(0.11)
(2.34)
(0.78)
(0.1)
Sortino Ratio
0.0042
0.064
N/A
0.0211
0.0259
0.1272
0.0105
N/A
N/A
0.0115
Downside Variance
121.9
303.52
N/A
56.92
483.62
245.94
511.28
N/A
N/A
43.08
Standard Deviation
9.51
13.94
686.05
7.03
20.12
16.75
13.33
14.69
4.62
7.08
Kurtosis
0.9367
1.13
49.88
2.32
2.21
3.83
2.05
4.37
8.23
7.12
Potential Upside
18.52
24.5
50.0
11.11
35.42
45.24
20.0
16.82
5.31
7.64
Treynor Ratio
(0.07)
(0.73)
(11.99)
(0.14)
(0.16)
(0.88)
(0.11)
2.88
(4.99)
(1.63)
Maximum Drawdown
45.86
58.29
4848.99
36.6
94.02
92.05
67.29
82.6
36.36
29.6
Variance
90.5
194.2
470661.91
49.46
404.96
280.69
177.78
215.85
21.38
50.07
Market Risk Adjusted Performance
(0.06)
(0.72)
(11.98)
(0.13)
(0.15)
(0.87)
(0.10)
2.89
(4.98)
(1.62)
Risk Adjusted Performance
0.0157
0.075
0.1246
0.0306
0.0334
0.106
0.0255
(0.1)
(0.10)
0.021
Skewness
0.462
(0)
7.06
0.7979
0.2282
1.26
(0.27)
0.5067
1.35
1.36
Semi Deviation
7.45
12.98
N/A
5.7
17.61
10.74
11.29
N/A
N/A
5.78
Information Ratio
0.0048
0.08
0.1438
0.0226
0.0283
0.1191
0.0177
(0.13)
(0.15)
0.0107
Value At Risk
(13.33)
(28.29)
(25.00)
(10.34)
(24.69)
(24.56)
(31.58)
(29.29)
(6.67)
(9.76)
Expected Short fall
(11.24)
(10.55)
N/A
(6.89)
(16.96)
(16.92)
(14.94)
N/A
N/A
(5.03)
Downside Deviation
11.04
17.42
N/A
7.54
21.99
15.68
22.61
N/A
N/A
6.56
Semi Variance
55.57
168.47
N/A
32.54
310.28
115.43
127.54
N/A
N/A
33.4

Emmaus Life Competition Performance Charts

Five steps to successful analysis of Emmaus Life Competition

Emmaus Life's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Emmaus Life Sciences in relation to its competition. Emmaus Life's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Emmaus Life in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Emmaus Life's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Emmaus Life Sciences, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Emmaus Life position

In addition to having Emmaus Life in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Soft Drinks Thematic Idea Now

Soft Drinks
Soft Drinks Theme
Entities manufacturing and distributing non alcoholic beverages across different markets. The Soft Drinks theme has 48 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Soft Drinks Theme or any other thematic opportunities.
View All  Next Launch
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in population.
You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.

Other Consideration for investing in Emmaus OTC Stock

If you are still planning to invest in Emmaus Life Sciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Emmaus Life's history and understand the potential risks before investing.
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Money Managers
Screen money managers from public funds and ETFs managed around the world
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY